TriAvir (a triple combination of zidovudine, lamivudine and nevirapine used to treat HIV/AIDS) to Rwanda. Yet, so aggravating and "cumbersome" was the process that Apotex said in a 2011 press release that it would be reluctant to go through it again unless changes were made (www.apotex.com/apotriavir/default.asp).
Critics of Canada's regime, such as Richard Elliott, the executive director of the Canadian HIV/AIDS Legal Network, have charged that the legislation was essentially flawed on a wide variety of grounds: the list of pharmaceutical products that were eligible for export was too limited; the period of time that a generic could be exported was too short; the administrative roadblocks immense. A generic manufacturer had to file a licence application for every drug, for every amount produced and for every country to which it wanted to export a drug.
The framework "tends not to be particularly well-crafted for the realities of the parties that need to use it," Elliott says.
Efforts to eliminate some of the bottlenecks include a provision of a recent bill, "C-393: An Act to amend the Patent Act," which enables manufacturers to use a single license to export a drug to a low-and middle-income country (www.parl.gc.ca/HouseChamberBusiness/ChamberVoteDetail.aspx?Language=E&Mode =1&Parl=40&Ses=2&Vote=142). Proponents argue that amendment would help, as generic drug companies could release several deliveries of a medication to a poor country over time.
The European Union has now enacted compulsory licensing legislation but none of its member nations have actually used the law to get generics to low-income nations. Australia recently pledged to have legislation in place this year and Elliott surmises it could actually be the first "workable" law in the world.
The entire issue of compulsory licensing becomes that much more problematic once the impact of India's 2005 adoption of new patent laws (to comply with the World Trade Organization's Agreement on Trade Related Aspects of Intellectual Property Rights) is factored in. Essentially, India has served as the pharmacy to the developing world but now must comply with international law in the manufacture of all drugs patented after 1995, though it can continue to manufacture generics that were in production prior to 1995.
Exactly how developments in India will shake out is unclear, Elliott says, adding that there is world-wide need for a straightforward application process where developing countries and generic manufacturers understand exactly how to apply for a compulsory license, as well as a need for specified formulas for calculating the level of royalties that will be paid to brand-name drug makers in cases where a knock-off is being produced.
Yet, for the most part, disputes over compulsory licensing legislation have been somewhat moot because India has been able to serve as a source of cheap generics for many nations, particularly those needing antiretroviral drugs to treat HIV/AIDS, t'Hoen says. There's simply been no need for low-and middle-income countries to turn to the European Union or Canada, where they might get mired in diplomatic trade disputes, when the drugs were readily available from India.
That's compounded by the fact the Europe has very limited production capacity to actually produce generics at a competitive price with facilities in India or China, where labour and active ingredient costs are much lower, she adds.
